Eli Lilly agrees to acquire sleep disorder drug developer Centessa Pharmaceuticals for approximately $7.8 billion, while ...

Officials at Caring Cross emphasize that the organization is dedicated to ensuring the global affordability of advanced therapies.

Discovery will enable tens of thousands of families affected by this previously hidden genetic condition to receive closure through genetic diagnosis.

Merck & Co. will apply the somatic genomics platform Quotient Therapeutics to discover novel drug targets in inflammatory bowel disease (IBD), through a collaboration that could generate up to $2.2 ...

Missing gut bacteria may prevent some people with celiac disease from fully benefiting from high-fiber supplements or diets [DrAfter123 / DigitalVision Vectors/] The autoimmune disorder celiac disease ...

A new CAR T-cell therapy attacks supportive cells in the tumor microenvironment that bear the surface protein, uPAR.

Over the past decade, scientists have identified numerous genetic variants that confer substantial risk for autism and other ...

AI is not overhyped. The potential requires equal attention to the less glamorous but more important role of data management.

Study identifies impaired ER-to-golgi ceramide transport as a key regulatory node underlying senescence-associated sphingolipid remodeling.

Large‑scale protein evolution model reveals that common ancestry, not selection or epistasis, is the dominant force limiting ...

The big pharma and AI drug developer expand on a partnership that launched with a 2023 software licensing accord.

Study findings indicate that environmentally relevant doses of OLA bioplastics may be “more toxic” to the placenta than ...